Pitavastatin suppresses acute and chronic rejection in murine cardiac allografts

Transplantation

Volumn 83, Issue 8, 2007, Pages 1093-1097

  Suzuki, Jun Ichi ^a   Koga, Noritaka ^a   Kosuge, Hisanori ^a   Ogawa, Masahito ^a   Haraguchi, Go ^a   Maejima, Yasuhiro ^a   Saiki, Hitoshi ^a   Isobe, Mitsuaki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chronic rejection; Heart transplantation; Statin

Indexed keywords

CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PITAVASTATIN; RIBONUCLEASE;

ACUTE GRAFT REJECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; BAGG ALBINO MOUSE; C57BL MOUSE; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CELL PROLIFERATION; CHRONIC GRAFT REJECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HLA MATCHING; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RIBONUCLEASE PROTECTION ASSAY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ANIMALS; CELL PROLIFERATION; CHOLESTEROL; CHRONIC DISEASE; CYTOKINES; GENE EXPRESSION REGULATION; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MICE; MYOCYTES, SMOOTH MUSCLE; QUINOLINES; SPLEEN; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TRIGLYCERIDES;

EID: 34247542477     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000259650.67061.16     Document Type: Article

References (30)

1. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: Eighteenth Official Report-2001. J Heart Lung Transplant 2001; 20: 805.
2. Katznelson S. Effect of HMG-CoA reductase inhibitors on chronic allograft rejection. Kidney Int Suppl 1999; 71: S117.
3. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996; 61: 1469.
4. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
5. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc 2000; 32: 622.
6. Kato T, Tokoro T, Namii Y, et al. Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease. Transplant Proc 2000; 32: 331.
7. Shimizu K, Aikawa M, Takayama K, Libby P, Mitchell RN. Direct antiinflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins. Circulation 2003; 108: 2113.
8. Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Int Suppl 1995; 52: S112.
9. Gregory CR, Katznelson S, Griffey SM, Kyles AE, Berryman ER. Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts. Transplantation 2001; 72: 989.
10. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399.
11. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687.
12. Isobe M, Kosuge H, Suzuki J. T cell costimulation in the development of cardiac allograft vasculopathy: Potential targets for therapeutic interventions. Arterioscler Thromb Vasc Biol 2006; 26:1447.
13. Kohno M, Shinomiya K, Abe S, et al. Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res 2002; 25: 279.
14. Isobe M, Suzuki J, Yamazaki S, et al. Regulation by differential development of Th1 and Th2 cells in peripheral tolerance to cardiac allograft induced by blocking ICAM-1/LFA-1 adhesion. Circulation 1997; 96: 2247.
15. Kosuge H, Suzuki J, Gotoh R, et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 2003; 75: 1374.
16. Koga N, Suzuki J, Kosuge H, et al. Blockade of the interaction between PD-1 and PD-L1 accelerates graft arterial disease in cardiac allografts. Arterioscler Thromb Vasc Biol 2004; 24: 2057.
17. Suzuki H, Yamazaki H, Aoki T, et al. Hypolipidemic effect of NK-104 and other 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in guinea pigs. Arzneimittelforschung 2001; 51: 38.
18. Suzuki J, Isobe M, Morishita R, et al. Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide. Nat Med 1997; 3: 900.
19. Futamatsu H, Suzuki J, Kosuge H, et al. Attenuation of experimental autoimmune myocarditis by blocking activated T cells through inducible costimulatory molecule pathway. Cardiovasc Res 2003; 59: 95.
20. Silverman ES, Khachigian LM, Santiago FS, Williams AJ, Lindner V, Collins T. Vascular smooth muscle cells express the transcriptional corepressor NAB2 in response to injury. Am J Pathol 1999; 155: 1311.
21. Onai Y, Suzuki J, Kakuta T, et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. Cardiovasc Res 2004; 63: 51.
22. Mehra MR, Uber PA, Vivekananthan K, et al. Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival. J Am Coll Cardiol 2002; 40: 1609.
23. Azuma RW, Suzuki J, Ogawa M, et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. Cardiovasc Res 2004; 64: 412.
24. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383.
25. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301.
26. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001.
27. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615.
28. Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: A four-year randomized trial. Circulation 1997; 96: 1398.
29. Kosuge H, Suzuki J, Kakuta T, et al. Attenuation of graft arterial disease by manipulation of the LIGHT pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1409.
30. Yamakawa T, Tanaka S, Kamei J, Kadonosono K, Okuda K. Pitavastatin inhibits vascular smooth muscle cell proliferation by inactivating extracellular signal-regulated kinases 1/2. J Atheroscler Thromb 2003; 10: 37.